Global Dry Powder Inhaler Devices Pipeline Report 2022 – Players Include AstraZeneca, Bayer, Cambridge Healthcare Innovations and Circassia – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder.

Companies Mentioned

• Acorda Therapeutics Inc
• Adamis Pharmaceuticals Corp
• Advent Pharmaceuticals Pty Ltd
• Aespira Ltd.
• AKELA Pharma Inc. (Inactive)
• AstraZeneca Plc
• Bayer AG
• Cambridge Healthcare Innovations Ltd
• Circassia Group Plc
• Creare LLC
• Eli Lilly and Co
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd
• Hovione Technology Ltd
• Iconovo AB
• Lupin Pharmaceuticals Inc
• MannKind Corp
• Monash University
• Nektar Therapeutics
• Ology Bioservices Inc
• OPKO Health Inc
• OtiTopic Inc
• Phargentis SA
• Pharmaxis Ltd
• Quench Medical Inc
• Respira Therapeutics Inc
• Respirent Pharmaceuticals Co Ltd
• Sandoz International GmbH
• Sheffield Hallam University
• Shin Nippon Biomedical Laboratories Ltd
• Spyryx Biosciences Inc (Inactive)
• Sun Pharma Advanced Research Company Ltd
• United Therapeutics Corp
• University of Kansas
• University of Sydney
• University of Texas Medical Branch at Galveston
• Vectura Group Plc
• Verona Pharma Plc
• Virginia Commonwealth University

Scope

• Extensive coverage of the Dry Powder Inhaler Devices under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to –

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Products under Development

3.1 Dry Powder Inhaler Devices – Pipeline Products by Stage of Development

3.2 Dry Powder Inhaler Devices – Pipeline Products by Territory

3.3 Dry Powder Inhaler Devices – Pipeline Products by Regulatory Path

3.4 Dry Powder Inhaler Devices – Pipeline Products by Estimated Approval Date

3.5 Dry Powder Inhaler Devices – Ongoing Clinical Trials

4 Dry Powder Inhaler Devices – Pipeline Products under Development by Companies

4.1 Dry Powder Inhaler Devices Companies – Pipeline Products by Stage of Development

4.2 Dry Powder Inhaler Devices – Pipeline Products by Stage of Development

5 Dry Powder Inhaler Devices Companies and Product Overview

6 Dry Powder Inhaler Devices- Recent Developments

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/mdzqcb

Source: GlobalData

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900